pathologic response

Enhanced Pathologic Response in Head and Neck Squamous Cell Carcinoma with Neoadjuvant Chemoimmunotherapy

By MedXY 08/25/2026

Neoadjuvant chemoimmunotherapy significantly improves pathologic response rates in resectable head and neck squamous cell carcinoma compared to immunotherapy alone, potentially transforming preoperative treatment strategies.

news Oncology Otorhinolaryngology

Enhanced Pathologic Responses with Neoadjuvant Chemoimmunotherapy in Resectable Head and Neck Squamous Cell Carcinoma

By MedXY 08/24/2026

Neoadjuvant chemoimmunotherapy significantly improves pathologic complete and major responses compared to immunotherapy alone in resectable head and neck squamous cell carcinoma, suggesting a promising avenue to improve treatment outcomes.

Clinical Updates news Oncology

Redefining Success in Neoadjuvant Therapy for Pancreatic Cancer: The Prognostic Significance of Major Pathologic Response

By MedXY 03/23/2026

This review evaluates the prognostic value of Major Pathologic Response (MPR) in pancreatic ductal adenocarcinoma, analyzing its impact on survival and its potential to guide personalized adjuvant treatment strategies.

news Oncology Otorhinolaryngology Pathology & Lab Medicine

Pathologic Response Predicts Disease-Free Survival in Neoadjuvant Immunotherapy for Mucosal HNSCC

By MedXY 12/22/2025

A meta-analysis of 11 trials shows that partial and major pathologic responses after neoadjuvant immunotherapy significantly correlate with improved disease-free survival in mucosal HNSCC, suggesting these metrics serve as viable surrogate endpoints for clinical outcomes.

news Oncology Otorhinolaryngology

Pathologic Response to Neoadjuvant Nivolumab Predicts Improved Survival in HPV‑Negative Head and Neck Cancer

By MedXY 11/21/2025

A pooled analysis of two neoadjuvant nivolumab trials found that pathologic treatment effect >57% is associated with markedly improved 3‑year disease‑free and overall survival in HPV‑negative resectable HNSCC, suggesting pTE may be a useful early surrogate biomarker.